EV
EVE.AU EVE Health Group Limited
- Market cap
- AUD 4.76M
- P/E
- -
- P/B
- 1.21x
- ROE
- -47.9%
- Dividend yield
- -
- Fundamental score
- 0.6/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is EVE.AU undervalued?
Graham numberThe Graham number of EVE Health Group Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
EVE Health Group Limited fundamental analysis
2 of 18 checks passedROE 0/2
Low return on equity (-47.9%), below 10%.
ROA 0/1
Return on assets (-44.2%) is below the industry median (3.0%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (43.6%) is above the industry median (-3.8%).
Revenue Growth 0/2
Revenue shrank 20.9% a year over the past 3 years.
Leverage 2/2
Total assets are 1.1x equity, within a prudent level for a financial company.
Equity Growth 0/1
Shareholders' equity did not grow over the past 5 years.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (1.2x) is above the industry median (0.9x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
EVE Health Group Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About EVE Health Group Limited
EVE Health Group Limited, a life sciences and healthcare company, engages in the development and commercialization of pharmaceutical products in Australia. It operates in two segments, Meluka (Branded Wellness Consumer Products) and Nextract (Pharmaceutical Products and Intellectual Property). Its lead product is the Dyspro, a formulation developed to address dysmenorrhoea and Endometriosis Pain; and Libbo, an oral dissolving film for erectile dysfunction. The company also d…
Full company profileEVE Health Group Limited financial statements
EVE Health Group Limited annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 250.00 | 18.9K | 1.60M | 2.31M | 2.80M | 2.01M | 2.33M | 2.13M | 1.73M | 1.15M |
| Gross Profit | 245.00 | 18.9K | -37.5K | 874K | -713K | -1.00M | 828K | 877K | 824K | -107K |
| Operating Income | -902K | -1.44M | -2.14M | -2.62M | -3.83M | -3.88M | -2.28M | -1.54M | -1.43M | -1.90M |
| EBITDA | -900K | 19.2K | -2.39M | -2.72M | -2.79M | -4.53M | -2.18M | -1.51M | -1.43M | -1.77M |
| Net Income | -1.39M | -1.88M | -2.64M | -2.40M | -3.63M | -5.37M | -4.04M | -1.90M | -1.58M | -1.89M |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | -0.01 |
| Balance Sheet | ||||||||||
| Total Assets | 3.07M | 7.46M | 8.78M | 14.1M | 11.9M | 8.07M | 4.13M | 2.52M | 4.12M | 4.28M |
| Total Liabilities | 294K | 76.8K | 2.93M | 1.12M | 1.74M | 1.14M | 1.01M | 1.30M | 572K | 330K |
| Shareholders' Equity | 2.78M | 7.38M | 5.85M | 13.0M | 10.2M | 6.93M | 3.12M | 1.22M | 3.55M | 3.95M |
| Cash & Short-term Investments | 260K | 3.91M | 340K | 5.14M | 3.16M | 1.10M | 192K | 106K | 903K | 1.24M |
| Total Debt | - | - | 1.30M | 584K | 1.01M | 492K | 4.28K | 74.9K | 91.3K | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | -559K | -809K | -1.07M | -3.16M | -2.24M | -3.77M | -1.65M | -1.11M | -1.62M | -1.74M |
| Capital Expenditure | 63.4K | 63.4K | 63.4K | 323K | 263K | 26.0K | 1.63K | 4.00 | 3.00 | 1.90K |
| Free Cash Flow | -559K | -809K | -1.13M | -3.48M | -2.51M | -3.80M | -1.65M | -1.11M | -1.62M | -1.74M |
| Ratios | ||||||||||
| ROE | -49.9% | -25.5% | -45.1% | -18.5% | -35.6% | -77.5% | -129.4% | -155.3% | -44.5% | -47.9% |
| ROA | -45.2% | -25.2% | -30.1% | -17.0% | -30.5% | -66.5% | -97.8% | -75.3% | -38.3% | -44.2% |
| Net Profit Margin | -554,941.2% | -9,945.0% | -165.1% | -103.9% | -129.6% | -267.4% | -173.5% | -89.1% | -91.1% | -164.0% |
| Debt to Equity | - | - | 0.22x | 0.04x | 0.10x | 0.07x | 0.00x | 0.06x | 0.03x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
EVE Health Group Limited dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | AUD 278K | 0.00 | - |
| 2022 | AUD 1.71M | 0.00 | - |
| 2021 | AUD 610K | 0.00 | - |
| 2020 | AUD 7.88M | 0.00 | - |
| 2019 | AUD 892K | 0.00 | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:40 on Jun 2, 2025.
Who owns EVE Health Group Limited
- Insiders 64.90%
- Institutions 0.00%
- Public & others 35.10%
- Shares outstanding 352M
- Free float 116M
EVE Health Group Limited company profile
- Company name
- EVE Health Group Limited
- Ticker
- EVE.AU
- ISIN
- AU000000EVE3
- Exchange
- Australian Securities Exchange
- Sector
- Consumer Defensive
- Industry
- Capital Markets
- Fiscal year end
- June
- Address
- 245 Churchill Avenue, Subiaco, WA, Australia, 6008
- Phone
- 61 8 6465 5500
- Website
- evehealthgroup.com.au
About EVE Health Group Limited
EVE Health Group Limited, a life sciences and healthcare company, engages in the development and commercialization of pharmaceutical products in Australia. It operates in two segments, Meluka (Branded Wellness Consumer Products) and Nextract (Pharmaceutical Products and Intellectual Property). Its lead product is the Dyspro, a formulation developed to address dysmenorrhoea and Endometriosis Pain; and Libbo, an oral dissolving film for erectile dysfunction. The company also develops Apixaban to treat anticoagulation. The company was formerly known as EVE Investments Limited. EVE Health Group Limited was incorporated in 2003 and is based in Subiaco, Australia.
EVE Health Group Limited management
3- Mr. Benedict James RohrChief Executive Officer
- Dr. Stuart GunzburgCSO & Executive Director
- Mr. Steven Luke Jackson BEc, C.P.A.CFO & Company Secretary